SEC Form 4 · accession 0001753159-26-000020
Guardant Health, Inc. · GH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
AmirAli Talasaz
Officer — Co-Chief Executive Officer · Director
Period of report
Aug 21, 2026
Accepted (ET)
Aug 24, 2026 · 5:21 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001576280
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 21, 2026 | S | 9,023 | $168.1958 | D | 65,977 | I | Shares held by the Talasaz Family Foundation |
| Common StockF2 | Aug 21, 2026 | S | 20,888 | $169.1618 | D | 45,089 | I | Shares held by the Talasaz Family Foundation |
| Common StockF3 | Aug 21, 2026 | S | 7,589 | $170.2862 | D | 37,500 | I | Shares held by the Talasaz Family Foundation |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.81 to $168.60. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.87 to $169.73. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.88 to $170.50. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.